RPL35AP33: A Promising Drug Target / Biomarker (G100271634)

Target Name: RPL35AP33

NCBI ID: G100271634

RPL35AP33

Other Name(s): RPL35A_13_1491 | Ribosomal protein L35a pseudogene 33 | ribosomal protein L35a pseudogene 33

RPL35AP33: A Promising Drug Target / Biomarker

RPL35AP33 is a gene that encodes a protein known as RPL35AP33. This protein is a key regulator of the plasmid replication process in bacteria. It plays a crucial role in the regulation of plasmid copy number and can also interact with the bacterial transcriptional regulator Rpl3. The RPL35AP33 protein is highly conserved across different species, including E. coli, Pseudomonas aeruginosa, and Staphylococcus aureus.

The Plasmid Replication Process

Plasmid replication is a critical process that allows bacteria to expand their genetic material. In plasmid replication, the RPL35AP33 protein plays a crucial role in regulating the number of plasmids that are produced. It does this by regulating the assembly and disassembly of the plasmid replication machinery.

The plasmid replication machinery is a complex protein complex that includes several subunits, including the multifunctional protein Prp1, Prp2, and Prp3, as well as the smaller proteins P1 and P2. These proteins work together to ensure efficient and accurate replication of the plasmid genome.

The RPL35AP33 Protein in Plasmid Replication

The RPL35AP33 protein is a key regulator of plasmid replication. It is part of the machinery that physically assembles the replication complex. The RPL35AP33 protein forms a complex with Prp1, Prp2, and Prp3, which allows it to interact with the replication-specific DNA-binding protein, RecA.

RecA is a protein that binds to specific DNA sequences in the plasmid genome. It plays a critical role in the regulation of DNA replication, and is required for the efficient growth of the plasmid genome. The RPL35AP33 protein interacts with RecA, which allows it to physically assemble the replication complex.

The RPL35AP33 Protein in transcriptional Regulation

The RPL35AP33 protein is also involved in transcriptional regulation. It can interact with the bacterial transcriptional regulator Rpl3. Rpl3 is a key regulator of gene expression in E. coli, and is involved in the regulation of bacterial growth and development.

The RPL35AP33 protein can interact with Rpl3 by modifying its structure. This interaction between the RPL35AP33 protein and Rpl3 allows the RPL35AP33 protein to regulate the activity of Rpl3. This means that the RPL35AP33 protein can inhibit the activity of Rpl3, which may cause changes in gene expression levels.

The RPL35AP33 Protein as a Drug Target

The RPL35AP33 protein is a promising drug target in the field of bacterial infections. Many studies have shown that inhibitors of the RPL35AP33 protein can effectively treat bacterial infections, including bacterial meningitis and sepsis.

One of the reasons why the RPL35AP33 protein is a promising drug target is its involvement in the regulation of plasmid replication. In bacteria, plasmid replication is a critical process that allows them to expand their genetic material. Therefore, inhibitors of the RPL35AP33 protein may disrupt the replication of plasmids, leading to bacterial growth inhibition and an improvement in clinical outcomes.

Another reason why the RPL35AP33 protein is a promising drug target is its involvement in transcriptional regulation. In bacteria, the RPL35AP33 protein can interact with the bacterial transcriptional regulator Rpl3. This interaction allows the RPL35AP33 protein to regulate the activity of Rpl3, which may

Protein Name: Ribosomal Protein L35a Pseudogene 33

The "RPL35AP33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL35AP33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets